Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AdvisorShares Psychedelics ETF (NY:PSIL)

16.24 -0.63 (-3.73%)
Official Closing Price Updated: 8:00 PM EST, Feb 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about AdvisorShares Psychedelics ETF

< Previous 1 2 3 4 5 Next >
News headline image
Psychedelics Break Out Of The Fringe Under RFK Jr’s 2025 Reset — But Did MNMD Or CMPS Own The Year? ↗
Regulatory thaw, political backing, and late-stage data are propelling psychedelic drugmakers into the biotech spotlight — with Compass Pathways and Mind Medicine leading the charge. 
Via Stocktwits
Topics ETFs
News headline image
Optimism Flows From Pot To Psychedelics: Atai Beckley, Supernus Stocks Rise After Analyst Flags Positive Tailwinds From Trump’s Marijuana Order ↗
Jefferies sees restrictions around non-recreational psychedelics eventually loosen up. 
Via Stocktwits
Topics Cannabis ETFs Government
News headline image
Why Did KTTA Stock Soar A Whopping 48% Today? ↗
The company announced the pricing of a public offering of 80 million shares of its common stock and said that the offering will extend its cash runway through at least the first half of 2028. 
Via Stocktwits
NEUP Shares Rise Pre-Market As It Explores Strategic Alternatives, Including Potential Acquisition ↗
Via Stocktwits
News headline image
Quantum Biopharma Reports Positive Phase 1 Safety For Multiple Sclerosis Drug ↗
Quantum Biopharma's subsidiary, Huge Biopharma Australia, has cleared a regulatory milestone for its neuroprotective compound, Lucid-MS, in a Phase 1 trial. 
Via Benzinga
News headline image
Compass Pathways Stock Slumps After Positive Late-Stage Trial Results From Psychedelic Drug ‘Underwhelm’ Analysts ↗
The company said it will discuss the “highly statistically significant and clinically meaningful” data with the U.S. Food and Drug Administration, which has yet to review it. 
Via Stocktwits
News headline image
Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors ↗
Psychedelics litigator Matthew Zorn joins HHS under RFK Jr. to lead policy. What it means for CMPS, MNMD, CYBN, PSIL & more. 
Via Benzinga
Topics Government
News headline image
5 ETFs That Beat Market Turmoil With Gains Last Week ↗
Last week had Wall Street facing volatility, tech earnings disappointments, mixed labor data, and rising inflation fears. Gold hit record highs. 
Via Benzinga
Topics ETFs Economy
News headline image
High-Momentum ETFs Leading the Market This Year
Momentum investors looking to start 2025 off on good footing might look no further than these high-flying ETFs, each of which has returned 14% or more in 2025. 
Via MarketBeat
Topics ETFs
News headline image
Small-Cap NRx Pharma’s Stock Draws Heavy Retail Buzz After Securing $27M Funding ↗
Chairman Jonathan Javitt said the resources committed are expected to bring NRx to the $100 million revenue threshold. 
Via Stocktwits
News headline image
Mind Medicine Stock Rises As Evercore Projects 200% Upside On LSD Formulation: Retail Turns Bullish ↗
The brokerage also pointed to potential large-scale expansion opportunities and emphasized the growing acceptance of psychedelics in future treatment paradigms. 
Via Stocktwits
News headline image
5 Best-Performing Sector ETFs Of Q4 ↗
In this article, we have highlighted five top-performing ETFs from different sectors that were the leaders in the fourth quarter. 
Via Talk Markets
Topics ETFs
News headline image
Why Is Penny Stock Clearmind Gaining Today? ↗
Clearmind Medicine's stock rose 63.9% after receiving IRB approval for its Phase I/IIa trial of CMND-100, a drug for alcohol use disorder. 
Via Benzinga
News headline image
5 Best-Performing Sector ETFs Midway In Q4 ↗
In this article, we have highlighted five top-performing ETFs from different sectors that were the leaders over the past month. 
Via Talk Markets
Topics ETFs
News headline image
Top And Flop ETFs Of The First Half ↗
In this article, we have highlighted three ETFs each from the best and worst-performing zones in the first half of 2024. 
Via Talk Markets
Topics ETFs
News headline image
Best And Worst ETF Zones Of Q2 ↗
After the worst monthly decline in many months in April, global stock markets have staged a nice comeback on renewed Fed rate cut bets, ongoing artificial intelligence (AI) developments and strong... 
Via Talk Markets
Topics Artificial Intelligence ETFs Economy
News headline image
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment ↗
FDA panel rejects MDMA therapy for PTSD, citing lack of evidence for benefits outweighing risks. Psychedelic stocks take a hit, with CYBN, MNMD, and ATAI down. FDA not bound by decision. 
Via Benzinga
News headline image
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More ↗
 
Via Benzinga
News headline image
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence ↗
 
Via Benzinga
News headline image
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More ↗
 
Via Benzinga
Topics Economy
News headline image
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More ↗
 
Via Benzinga
News headline image
Mental Health Mavericks: 3 Stocks Changing the Game ↗
Except for the psychedelics movement, there seem to be very few mental health stocks to buy that are making money. 
Via InvestorPlace
News headline image
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More ↗
 
Via Benzinga
News headline image
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More ↗
New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian... 
Via Benzinga
News headline image
Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More ↗
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD 
Via Benzinga
News headline image
Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More ↗
Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury 
Via Benzinga
News headline image
Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More ↗
President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 National Defense Authorization Act (NDAA), large-scale legislation that also... 
Via Benzinga
News headline image
Psychedelic Drug Stocks Index Up In December; Down YTD ↗
The constituents in the Index are up 9.1% MTD, on average, are down 29.2% YTD, on average, and are now down 85.9% from their highs in 2021. 
Via Talk Markets
News headline image
Psyched: Biden's Big Decision On Psychedelics Therapy; LSD Anxiety Results; Matthew Perry Autopsy And More ↗
Biden To Decide On Psychedelic Therapy Bill 
Via Benzinga
News headline image
Psychedelic Drug Stocks Index Declined 1.6% This Week ↗
Our Psychedelic Drug Stocks Index is now down 11.5% YTD. The AdvisorShares Psychedelic ETF (PSIL), in comparison, remains down 28.8% YTD. 
Via Talk Markets
Topics ETFs
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.